RAF Suppression Synergizes with MEK Inhibition in KRAS Mutant Cancer Cells

KRAS is the most frequently mutated oncogene in human cancer, yet no therapies are available to treat KRAS mutant cancers. We used two independent reverse genetic approaches to identify components of the RAS-signaling pathways required for growth of KRAS mutant tumors. Small interfering RNA (siRNA)...

Celý popis

Podrobná bibliografie
Hlavní autoři: Simona Lamba, Mariangela Russo, Chong Sun, Luca Lazzari, Carlotta Cancelliere, Wipawadee Grernrum, Cor Lieftink, Rene Bernards, Federica Di Nicolantonio, Alberto Bardelli
Médium: Článek
Jazyk:English
Vydáno: Elsevier 2014-09-01
Edice:Cell Reports
On-line přístup:http://www.sciencedirect.com/science/article/pii/S2211124714006172